硼替佐米靶向多发性骨髓瘤蛋白酶体：作为一线单药、干细胞移植诱导方案和维持治疗的治疗获益最新进展。
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
机构信息
Translational Genomics Section, Medical Oncology Branch, National Cancer Institute, Magnuson Cancer Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Am J Ther. 2012 Mar;19(2):133-44. doi: 10.1097/MJT.0b013e3181ff7a9e.
Abstract
Bortezomib is the first therapeutic inhibitor of the proteasome that has demonstrated a significant clinical response in patients with otherwise refractory or rapidly advancing disease. Bortezomib has received US Federal Drug Administration approval for the treatment of the hematologic malignancies such as multiple myeloma and mantle cell lymphoma. Herein, the use of bortezomib as an upfront therapy, as an induction regimen before stem-cell transplantation and as maintenance therapy in the treatment of multiple myeloma is discussed.
摘要
硼替佐米是第一个蛋白酶体抑制剂治疗药物，在其他治疗方法无效或疾病快速进展的患者中显示出显著的临床疗效。硼替佐米已获得美国食品和药物管理局批准，用于治疗血液系统恶性肿瘤，如多发性骨髓瘤和套细胞淋巴瘤。本文讨论了硼替佐米作为一线治疗药物、干细胞移植前诱导方案以及多发性骨髓瘤维持治疗的应用。
相似文献
1
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
Am J Ther. 2012 Mar;19(2):133-44. doi: 10.1097/MJT.0b013e3181ff7a9e.
2
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Cancer. 2005 Nov 1;104(9):1794-807. doi: 10.1002/cncr.21414.
3
Update on the proteasome inhibitor bortezomib in hematologic malignancies.
Clin Lymphoma. 2004 Mar;4(4):230-7. doi: 10.3816/clm.2004.n.003.
4
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.
5
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Cancer Treat Rev. 2005 Dec;31(8):591-602. doi: 10.1016/j.ctrv.2005.10.001. Epub 2005 Nov 17.
6
Frontline treatment of multiple myeloma.
Hematology. 2012 Apr;17 Suppl 1:S101-4. doi: 10.1179/102453312X13336169156096.
7
Dissecting bortezomib: development, application, adverse effects and future direction.
Curr Pharm Des. 2013;19(18):3190-200. doi: 10.2174/13816128113199990338.
8
Carfilzomib: a novel second-generation proteasome inhibitor.
Future Oncol. 2011 May;7(5):607-12. doi: 10.2217/fon.11.42.
9
Current status of bortezomib in the treatment of multiple myeloma.
Curr Hematol Malig Rep. 2007 May;2(2):128-37. doi: 10.1007/s11899-007-0018-y.
10
Proteasome inhibition in the treatment of cancer.
Cell Cycle. 2005 Feb;4(2):290-6. Epub 2005 Feb 3.
引用本文的文献
1
PIM Kinases in Multiple Myeloma.
Cancers (Basel). 2021 Aug 26;13(17):4304. doi: 10.3390/cancers13174304.
2
Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model.
Int J Mol Sci. 2021 May 25;22(11):5570. doi: 10.3390/ijms22115570.
3
Increased expression of miR-27 predicts poor prognosis and promotes tumorigenesis in human multiple myeloma.
Biosci Rep. 2019 Apr 9;39(4). doi: 10.1042/BSR20182502. Print 2019 Apr 30.
4
Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Oncotarget. 2017 Jan 31;8(5):7647-7665. doi: 10.18632/oncotarget.13831.
5
Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.
Leuk Res. 2016 Feb;41:85-95. doi: 10.1016/j.leukres.2015.12.005. Epub 2015 Dec 19.
6
Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses.
J Adv Pract Oncol. 2015 Jul-Aug;6(4):308-18. doi: 10.6004/jadpro.2015.6.4.2. Epub 2015 Jul 1.
本文引用的文献
1
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
J Clin Oncol. 2010 Oct 20;28(30):4621-9. doi: 10.1200/JCO.2009.27.9158. Epub 2010 Sep 7.
2
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Lancet Oncol. 2010 Oct;11(10):934-41. doi: 10.1016/S1470-2045(10)70187-X. Epub 2010 Aug 23.
3
Union of forces advances myeloma care.
Blood. 2010 Aug 5;116(5):674-5. doi: 10.1182/blood-2010-04-281212.
4
Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.
Clin Cancer Res. 2010 Aug 15;16(16):4094-104. doi: 10.1158/1078-0432.CCR-09-2882. Epub 2010 Aug 3.
5
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.
Leukemia. 2010 Aug;24(8):1406-11. doi: 10.1038/leu.2010.129. Epub 2010 Jun 10.
6
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Blood. 2010 Sep 2;116(9):1515-23. doi: 10.1182/blood-2010-03-272567. Epub 2010 Jun 4.
7
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Leukemia. 2010 Jul;24(7):1350-6. doi: 10.1038/leu.2010.116. Epub 2010 May 27.
8
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Blood. 2010 Aug 5;116(5):679-86. doi: 10.1182/blood-2010-02-268862. Epub 2010 Apr 12.
9
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
J Clin Oncol. 2010 Apr 20;28(12):2077-84. doi: 10.1200/JCO.2009.23.7172. Epub 2010 Mar 22.
10
Hematopoietic stem cell transplantation for multiple myeloma beyond 2010.
Blood. 2010 May 6;115(18):3655-63. doi: 10.1182/blood-2009-08-238196. Epub 2010 Mar 4.
Zotero 插件